© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 22, 1848-1849,
November 15, 2000
© 2000 Oxford University Press
BRIEF COMMUNICATION |
Analysis of Fibroblast Growth Factor Receptor 3 S249C Mutation in Cervical Carcinoma
Affiliation of authors: C. J. Yee, J. Boyd (Gynecology and Breast Research Laboratory, Departments of Surgery and Human Genetics), O. Lin (Department of Pathology), Memorial Sloan-Kettering Cancer Center, New York, NY.
Correspondence to: Jeff Boyd, Ph.D., Department of Surgery, Box 201, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021 (e-mail: boydj@mskcc.org).
Carcinoma of the uterine cervix is the most common gynecologic cancer encountered worldwide (1). Infection with human papillomavirus (HPV) is a major risk factor in cervical cancer, and HPV is present in nearly all cervical carcinomas examined (2). Additional recurrent genetic alterations in cervical cancer include loss of heterozygosity at several chromosomal regions, including 3p, 4p, 5p, 6p, 11q, 17p, 18q, and 19q, and gene amplification on chromosome 3q (3). However, specific genes at these
NOTES
REFERENCES